Latest News
- Min. Nadda Unveils ?13,000-Crore Bio-Pharma SHAKTI and Chemical Parks Push to Expand India’s Global Chemicals and Biologics Footprint
- Aurobindo Pharma Subsidiary Launches Generic Cancer Drug in US, Expands Oncology Portfolio in Global Generics Market
- KIMS Hospitals Introduces Adaptive Deep Brain Stimulation in India for Advanced Parkinson’s Treatment
Geropharm introduces a novel medication for the remedy of ADHD
- By Newsdesk
- Russia
- Jun 28, 2023
Geropharm, a biotechnology company, has recently introduced a new medication that incorporates atomoxetine as its active ingredient. This drug is specifically developed to address attention deficit hyperactivity disorder (ADHD) in both children (aged six and above) and adults.
Atomoxetine has undergone rigorous research in the form of over 300 meta-analyses and randomized clinical trials, establishing it as the most extensively studied compound for ADHD treatment in the Russian Federation.
With its robust body of evidence, atomoxetine stands out as the most substantiated option for ADHD treatment. Geropharm emphasizes that their medication, called "Cogniter," enhances attention, normalizes behavior, and targets the core factors involved in ADHD by optimizing neurotransmitter balance.